Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × FP-1039 × Clear all

Phase

Status

Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 1

Interventions

Radiotherapy 106 Cyclophosphamide 106 Cisplatin 102 pembrolizumab 97 Paclitaxel 83 Carboplatin 83 Gemcitabine 76 Nivolumab 69 Magnetic Resonance Spectroscopy 69 Fluorouracil 64 Dexamethasone 60 Bevacizumab 59 Radiosurgery 56 Docetaxel 56 Rituximab 50 Oxaliplatin 48 Leucovorin 48 Capecitabine 47 Biopsy 47 fludarabine 45 Doxorubicin 42 durvalumab 40 Drug Therapy 39 Pemetrexed 37 fludarabine phosphate 36 Etoposide 36 Cytarabine 35 Radiation 33 Lenalidomide 32 Specimen Handling 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01244438 2021-12-13

Study of FP-1039 in Subjects With Endometrial Cancers

Five Prime Therapeutics, Inc.

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡